Summary
Horizon Pharma, Inc. (Horizon Pharma) is a specialty pharmaceutical company. It undertakes the development and commercialization of medical products for the treatment of pain, arthritis and inflammatory diseases. The company’s pipeline product portfolio includes products such as Duexis, Rayos, Vimovo and Lodotra. Its products find application in the treatment of pain, osteoarthritis, rheumatoid arthritis, polymyalgia rheumatic, asthma, chronic obstructive pulmonary disease, ankylosing spondylitis and various other conditions. The company provides products and services to patients and healthcare professionals in the US. It operates through its subsidiaries in UK, Switzerland and Germany. Horizon Pharma is headquartered in Deerfield, Illinois, the US.
Horizon Pharma, Inc. (HZNP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Horizon Pharma, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 7
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 9
Horizon Pharma, Inc., Medical Devices Deals, 2008 to YTD 2014 10
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 11
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Sosei Sells Chronotherapeutics Patents To Nitec Pharma 13
Venture Financing 14
Horizon Pharma Secures US$35 Million In Venture Financing 14
Horizon Pharma Secures US$20 Million In Financing Round 15
Horizon Therapeutics Secures US$8 Million In Extended Series D Venture Financing 16
Horizon Therapeutics Secures US$12 Million In Series D Financing Round 17
Nitec Pharma Secures US$22.01 Million In Financing 18
Partnerships 20
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 20
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 21
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 22
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA 29
Mundipharma Enters Into Agreement With Nitec Pharma 30
Merger 31
Horizon Therapeutics Merges With Nitec Pharma To Form Horizon Pharma 31
Licensing Agreements 33
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 33
Equity Offering 34
Horizon Pharma Completes Public Offering Of Units For US$86 Million 34
Horizon Pharma Completes Private Placement Of Units For US$51 Million 36
Horizon Pharma Completes IPO Of Common Stock For US$49.5 Million 37
Debt Offering 39
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 39
Acquisition 41
Horizon Pharma Receives Antitrust Approval To Acquire Vidara Therapeutics International For US$660 Million In Reverse Acquisition 41
Horizon Pharma, Inc. - Key Competitors 43
Key Employees 44
Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 46
Methodology 46
About GlobalData 46
Contact Us 46
Disclaimer 46
List Of Tables
List of Tables
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Key Facts, 2013 1
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 1
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 1
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 1
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Horizon Pharma, Inc., Pharmaceuticals & Healthcare Deals By Type, 2008 to YTD 2014 7
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Horizon Pharma, Inc., Deals By Therapy Area, 2008 to YTD 2014 9
Horizon Pharma, Inc., Medical Devices Deals, 2008 to YTD 2014 10
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2008 to YTD 2014 11
Sosei Sells Chronotherapeutics Patents To Nitec Pharma 13
Horizon Pharma Secures US$35 Million In Venture Financing 14
Horizon Pharma Secures US$20 Million In Financing Round 15
Horizon Therapeutics Secures US$8 Million In Extended Series D Venture Financing 16
Horizon Therapeutics Secures US$12 Million In Series D Financing Round 17
Nitec Pharma Secures US$22.01 Million In Financing 18
Horizon Pharma And Mundipharma Amend Distribution Agreement For Lodotra 20
Mallinckrodt Enters Into Co-Promotion Agreement With Horizon Pharma For Duexis 21
Horizon Pharma Amends Co-Marketing Agreement With Mundipharma International For LODOTRA 22
Horizon Pharma Enters Into Distribution Agreement With Mundipharma International Corporation For LODOTRA 29
Mundipharma Enters Into Agreement With Nitec Pharma 30
Horizon Therapeutics Merges With Nitec Pharma To Form Horizon Pharma 31
Grunenthal Enters Into Licensing Agreement With Horizon Pharma For Duexis 33
Horizon Pharma Completes Public Offering Of Units For US$86 Million 34
Horizon Pharma Completes Private Placement Of Units For US$51 Million 36
Horizon Pharma Completes IPO Of Common Stock For US$49.5 Million 37
Horizon Pharma Completes Private Placement Of Notes Due 2018 For US$150 Million 39
Horizon Pharma Receives Antitrust Approval To Acquire Vidara Therapeutics International For US$660 Million In Reverse Acquisition 41
Horizon Pharma, Inc., Key Competitors 43
Horizon Pharma, Inc., Key Employees 44
Horizon Pharma, Inc., Subsidiaries 45
List Of Figures
List of Figures
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 1
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2008 to YTD 2014 6
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2008 to YTD 2014 7
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2008 to YTD 2014 8
Horizon Pharma, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2008 to YTD 2014 9
Horizon Pharma, Inc., Medical Devices Deals, 2008 to YTD 2014 10
